Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Aug 10, 2026 · Filed Aug 11, 2026
A board member of Charles River Laboratories sold $7.9M of Charles River Laboratories shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$7,901,575
Shares × reported transaction price
5 days after results of Aug 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $277.00 on Aug 10, 2026, at its 52-week high, after a 28% rise over the previous 30 trading days
52-week range $145.57 (Sep 25, 2025) to $277.00 (Aug 10, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $215.75 on Jun 26, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.0% | -0.4% | +2.4% |
| 30 days | -2.1% | -1.1% | -1.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Director sold ~$10.1M of Charles River Laboratories
Scheduled in advance